Clinical trials: Second Cancer
Leukemia, Myeloid, Chronic-Phase (CML-CP)
Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
The purpose of this study is to determine predictive value of Hammersmith score on Complete Cytogenetic Response (CCyR).
- Trial name
- NCT01188278
- Testing
- Imatinib
- Volunteers
- 173 people
- Sponsor
- Bristol-Myers Squibb
Urologic Neoplasms
Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients locally advanced, metastatic, or recurrent transitional cell…
- Trial name
- NCT00034177
- Testing
- S-8184 Paclitaxel Injectable Emulsion, Experimental Arm: TOCOSOL Paclitaxel
- Volunteers
- 27 people
- Sponsor
- Achieve Life Sciences
Ovarian Cancer, Platinum-sensitive Ovarian Cancer
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
This Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available…
- Conditions
- Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC
- Trial name
- RAINFOL-04 (NCT07225270)
- Testing
- Rina-S, Bevacizumab
- Where
- 34 sites in United States, Belgium and 6 more
- Volunteers
- 544 people
- Sponsor
- Genmab
Refractory Leukemia, Acute Myelogenous Leukemia
Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
This study was to evaluate the efficacy and safety of single agent oral panobinostat in patients who have refractory de novo or refractory secondary AML.
- Trial name
- NCT00880269
- Testing
- Panobinostat/LBH589
- Where
- 40 sites in United States, Australia and 10 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Ovarian Cancer
Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients
The objective is to evaluate the efficacy and safety of masitinib in combination with gemcitabine in refractory ovarian cancer patients.
- Trial name
- NCT02490488
- Testing
- Masitinib, Gemcitabine
- Where
- 6 sites in Algeria, France and 4 more
- Volunteers
- 248 people
- Sponsor
- AB Science
Prostatic Neoplasms
Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US
This study is conducted to estimate population-based incidence rates of second primary malignancies among patients with CRPC similar to those treated with Xofigo.
- Trial name
- NCT02788409
- Testing
- Not applicable for study
- Where
- United States
- Volunteers
- 2,234 people
- Sponsor
- Bayer
Colorectal Cancer
Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma
The primary objective of this study is to compare the additive efficacy of SIM versus placebo in combination with leucovorin (folinic acid), irinotecan, and fluorouracil (FOLFIRI) as measured by improvement in progression-free…
- Trial name
- NCT01479465
- Testing
- Simtuzumab, Leucovorin, Irinotecan
- Where
- 109 sites in United States, France and 5 more
- Volunteers
- 266 people
- Sponsor
- Gilead Sciences
Stomach Neoplasms, Esophageal Neoplasms
Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma
The purpose of this study is to assess objective tumor response in the single agent treatment of PEP02, irinotecan, or docetaxel for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
- Trial name
- NCT00813072
- Testing
- PEP02, irinotecan, docetaxel
- Where
- 22 sites in Bosnia and Herzegovina, Croatia and 4 more
- Volunteers
- 135 people
- Sponsor
- PharmaEngine
Metastatic Colorectal Cancer
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
ARQ 197 or placebo in combination with irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC), in participants with wild-type KRAS alleles who have failed front-line systemic therapy, to evaluate the…
- Trial name
- NCT01075048
- Testing
- Tivantinib, Cetuximab, Irinotecan
- Where
- 40 sites in United States, France and 3 more
- Volunteers
- 131 people
- Sponsor
- Daiichi Sankyo
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
This prospective, double-blind, randomized study will evaluate the safety and efficacy of two dose levels of erlotinib [Tarceva] on progression-free survival, response and disease control rates and overall survival in patients…
- Trial name
- NCT01183858
- Testing
- Erlotinib [Tarceva]
- Where
- 63 sites in China, Denmark and 7 more
- Volunteers
- 315 people
- Sponsor
- Hoffmann-La Roche
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or…
- Trial name
- PRESERVE 2 (NCT04799249)
- Testing
- Trilaciclib, Gemcitabine, Carboplatin
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- G1 Therapeutics, Inc.
Non-Small-Cell Lung Cancer
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
The purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer…
- Trial name
- NCT00049998
- Testing
- topotecan
- Where
- 114 sites in Australia, Austria and 29 more
- Volunteers
- 760 people
- Sponsor
- GlaxoSmithKline
Advanced Colorectal Cancer, Colorectal Cancer
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
Patients with histologically or cytologically confirmed metastatic colorectal cancer (CRC) who have failed a first-line chemotherapeutic regimen containing oxaliplatin and 5-fluorouracil (5-FU) with or without bevacizumab, with…
- Trial name
- NCT00498407
- Testing
- CP-4055
- Where
- 4 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Clavis Pharma
Biliary Tract Cancer, Cholangiocarcinoma
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
The study to evaluate M7824 monotherapy in participants with advanced or metastatic biliary tract cancer (BTC) who failed or were intolerant to first-line (1L) chemotherapy.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Trial name
- NCT03833661
- Testing
- M7824
- Where
- 33 sites in United States, China and 7 more
- Volunteers
- 159 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Carcinoma, Non-Small-Cell Lung
This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.
The purpose of this study is to compare the efficacy of ZD6474 and ZD1839 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
- Trial name
- NCT00059722
- Testing
- ZD6474, ZD1839
- Where
- 48 sites in United States, Argentina and 4 more
- Volunteers
- 160 people
- Sponsor
- Genzyme, a Sanofi Company
Small Cell Lung Cancer
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study designed to is to determine if the combination treatment can improve progression free survival (defined as the time from the date of…
- Trial name
- NCT02038647
- Testing
- Alisertib, Paclitaxel
- Where
- 61 sites in United States, Belgium and 8 more
- Volunteers
- 178 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Lung Cancer, Non-Small Cell Lung Cancer
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
The purpose of this study is to investigate the safety of patients in Asia with Non-Small Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third line treatment.
- Trial name
- CheckMate870 (NCT03195491)
- Testing
- Nivolumab
- Where
- 30 sites in China, Thailand
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb